These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8825138)

  • 21. The prognostic impact of some cell cycle regulatory proteins in Egyptian breast cancer patients.
    Kamel A; Mokhtar N; Elshakankiry N; Yassin D; Elnahass Y; Zakarya O; Elbasmy A; Elmetenawy W
    J Egypt Natl Canc Inst; 2006 Jun; 18(2):93-102. PubMed ID: 17496933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tissue pretreatment with formic acid might lower HercepTest scores in breast cancer.
    Fritzsche FR; Kristiansen G; Boesl A; Burkhardt M; Pahl S; Dankof A; Dietel M; Dahl E
    Diagn Mol Pathol; 2006 Dec; 15(4):237-42. PubMed ID: 17122652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
    D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
    Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors.
    Stierer M; Rosen H; Weber R; Hanak H; Spona J; Tüchler H
    Ann Surg; 1993 Jul; 218(1):13-21. PubMed ID: 8328824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: correlations with clinicopathologic tumor parameters and expression of AP-1 factors.
    Bamberger AM; Milde-Langosch K; Schulte HM; Löning T
    Horm Res; 2000; 54(1):32-7. PubMed ID: 11182633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Andersen J; Overgaard J
    Acta Oncol; 2008; 47(4):591-9. PubMed ID: 18465327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison between single saturating dose ligand binding assay and enzyme immunoassay for low-salt extractable oestrogen and progesterone receptors in breast cancer: a multicentre study.
    Gion M; Dittadi R; Leon AE; Bruscagnin G; Pelizzola D; Giovannini G; Giganti M; Messeri G; Quercioli M; Flamini E
    Eur J Cancer; 1991; 27(8):996-1002. PubMed ID: 1832912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
    Ning SF; Li JL; Luo CP; Wei CH; Lu YK; Liu HZ; Wei WE; Zhang LT
    Int J Clin Exp Pathol; 2014; 7(12):8740-7. PubMed ID: 25674240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of estrogen receptors in paraffin-embedded tissue. Techniques and the value in breast cancer treatment.
    Andersen J
    Acta Oncol; 1992; 31(6):611-27. PubMed ID: 1281648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer.
    Pérez-Fidalgo JA; Eroles P; Ferrer J; Bosch A; Burgués O; Martínez F; Bermejo B; Lluch A; González-Angulo AM
    Breast; 2013 Oct; 22(5):974-9. PubMed ID: 23809906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enzyme-linked immunosorbent assay of HER-2/neu gene product (p185) in breast cancer: its correlation with sex steroid receptors, cathepsin D and histologic grades.
    Marsigliante S; Muscella A; Ciardo V; Barker S; Leo G; Baker V; Mottaghi A; Vinson GP; Storelli C
    Cancer Lett; 1993 Dec; 75(3):195-206. PubMed ID: 7906196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical evaluation of ErbB-2 protein in tissue extract using an enzyme immuno assay (ErbB-2 EIA "Nichirei")].
    Sugano K; Kitajima M; Ishii M; Koyama H; Kasumi F; Demura R; Mori S; Ohkura H
    Gan To Kagaku Ryoho; 1994 Sep; 21(12):1957-66. PubMed ID: 7916182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay.
    Eppenberger-Castori S; Kueng W; Benz C; Caduff R; Varga Z; Bannwart F; Fink D; Dieterich H; Hohl M; Müller H; Paris K; Schoumacher F; Eppenberger U
    J Clin Oncol; 2001 Feb; 19(3):645-56. PubMed ID: 11157014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estrogen and progesterone receptors in breast cancer: comparison between enzyme immunoassay and computer-assisted image analysis of immunocytochemical assay.
    Cavaliere A; Bucciarelli E; Sidoni A; Bianchi G; Pietropaoli N; Ludovini V; Vitali R
    Cytometry; 1996 Sep; 26(3):204-8. PubMed ID: 8889392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
    Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
    Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue microarray-based immunohistochemical study can significantly underestimate the expression of HER2 and progesterone receptor in ductal carcinoma in situ of the breast.
    Lin Y; Hatem J; Wang J; Quinn A; Hicks D; Tang P
    Biotech Histochem; 2011 Oct; 86(5):345-50. PubMed ID: 20701550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients.
    Gago FE; Tello OM; Diblasi AM; Ciocca DR
    J Steroid Biochem Mol Biol; 1998 Dec; 67(5-6):431-7. PubMed ID: 10030692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
    Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
    Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of C-erbB-2 and hormone receptors' status in human benign and malignant breast lesions.
    Goussia A; Agnantis NJ; Athanassiadou S; Stefanou D
    Anticancer Res; 1995; 15(5B):2313-8. PubMed ID: 8572645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients.
    Aryandono T; Harijadi ; Ghozali A
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():600-6. PubMed ID: 10895217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.